Cwm LLC Increases Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Cwm LLC lifted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 79.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 66,972 shares of the company’s stock after acquiring an additional 29,614 shares during the period. Cwm LLC’s holdings in Xeris Biopharma were worth $368,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Xeris Biopharma by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock worth $273,000 after acquiring an additional 3,447 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Xeris Biopharma by 31.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company’s stock worth $55,000 after purchasing an additional 3,847 shares during the period. Prudential Financial Inc. lifted its holdings in shares of Xeris Biopharma by 23.4% during the fourth quarter. Prudential Financial Inc. now owns 36,945 shares of the company’s stock worth $125,000 after purchasing an additional 7,000 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Xeris Biopharma by 5.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 170,482 shares of the company’s stock worth $578,000 after purchasing an additional 9,506 shares during the period. Finally, NewEdge Advisors LLC acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth $34,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Xeris Biopharma news, insider Kevin Mcculloch bought 25,000 shares of Xeris Biopharma stock in a transaction on Friday, June 13th. The stock was bought at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the acquisition, the insider owned 1,708,585 shares in the company, valued at $7,483,602.30. The trade was a 1.48% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.47% of the company’s stock.

Xeris Biopharma Stock Performance

Xeris Biopharma stock opened at $5.02 on Friday. Xeris Biopharma Holdings, Inc. has a one year low of $2.10 and a one year high of $6.07. The business has a fifty day moving average of $4.82 and a two-hundred day moving average of $4.42. The company has a market cap of $785.03 million, a P/E ratio of -16.73 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million. Sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on XERS shares. Oppenheimer increased their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Friday, May 9th. Wall Street Zen downgraded Xeris Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, May 22nd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Xeris Biopharma has an average rating of “Moderate Buy” and an average price target of $6.25.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.